1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane,
1-MSPMPE,
dofetilide,
Tikosyn,
UK 68798,
UK-68,798,
Dofetilide,
115256-11-6,
Tikosyn,
Dofetilida,
Dofetilidum,
Dofetilidum [INN-Latin],
Dofetilida [INN-Spanish],
UK 68798,
UK-68798,
Dofetilide (Tikosyn),
UK-68,798,
UNII-R4Z9X1N2ND,
Dofetilide(Tikosyn),
UK 68,798,
C19H27N3O5S2,
beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide,
CHEMBL473,
R4Z9X1N2ND,
CHEBI:4681,
1-(4-Methanesulphonamidophenoxy)-2-[N-(4-methanesulphonamidophenethyl)-N-methylamino]ethane,
N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide,
N-[4-[2-[Methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]methanesulfonamide,
UK68798,
NCGC00164549-01,
UK 68789,
DSSTox_CID_26433,
DSSTox_RID_81610,
N-(4-(2-(methyl(2-(4-(methylsulfonamido)phenoxy)ethyl)amino)ethyl)phenyl)methanesulfonamide,
DSSTox_GSID_46433,
Xelide,
1-MSPMPE,
Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl)-,
N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide,
SMR000466333,
Tikosyn (TN),
Dofetilide [USAN:BAN:INN],
CAS-115256-11-6,
Dofetilide (JAN/USAN/INN),
Dofetilide;,
HSDB 7927,
Dofetilide [USAN:USP:INN:BAN],
Methanesulfonamide, N-[4-[2-[methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]-,
n-(4-(2-{2-(4-(methanesulphonamido)phenoxyl)-n-methylethylamino}ethyl)phenyl)-methanesulphonamide,
N-[4-(2-{2-[4-(methanesulphonamido)phenoxyl]-N-methylethylamino}ethyl)phenyl]-methanesulphonamide,
Tikosyn;UK68798,
AC1L2FYH,
AC1Q6VUS,
1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane,
SCHEMBL16135,
MLS000759442,
MLS001424185,
MLS006010154,
GTPL2604,
Dofetilide, >=98% (HPLC),
DTXSID5046433,
CTK8F9356,
KS-00000XNN,
IXTMWRCNAAVVAI-UHFFFAOYSA-N,
HMS2051N14,
HMS2089F03,
HMS2232H19,
HMS3261G03,
HMS3370B18,
HMS3393N14,
HMS3655A17,
HMS3715H20,
ZINC596731,
ACT04222,
BCP04770,
HY-B0232,
Tox21_112178,
Tox21_500351,
AC-385,
BDBM50031720,
FC0019,
MFCD00869707,
s1658,
AKOS005259921,
Tox21_112178_1,
API0002471,
BCP9000619,
CCG-101037,
CS-2200,
DB00204,
NC00287,
UK68789,
MRF-0000317,
NCGC00164549-02,
NCGC00261036-01,
AK161932,
AN-15862,
BC660134,
CC-27363,
CPD000466333,
I881,
LS-90151,
Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl),
SAM001246621,
SC-76467,
BCP0726000009,
AB0004775,
AB2000201,
TL8000450,
FT-0631076,
ST24046670,
SW197667-2,
A10328,
C07751,
D00647,
AB00639976-06,
AB00639976-08,
AB00639976_09,
256D116,
A803396,
C-22372,
SR-01000759368,
I06-0340,
J-003271,
SR-01000759368-4,
BRD-K86887724-001-05-6,
Dofetilide, United States Pharmacopeia (USP) Reference Standard,
1-(4-Methansulphonamidophenoxy)-2-[N-(4-methanesulphonamidophenethyl)-N-methylamino]ethane,
N-[4-[2-[2-(4-methanesulfonamidophenyl)ethyl-methylamino]ethoxy]phenyl]methanesulfonamide,
(Dofetilide) N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methylamino}-ethoxy)-phenyl]-methanesulfonamide,
N-[4-(2-{[2-(4-methanesulfonamidophenoxy)ethyl](methyl)amino}ethyl)phenyl]methanesulfonamide,
N-[4-(2-{[2-(4-methanesulfonylamino-phenoxy)-ethyl]-methyl-amino}-ethyl)-phenyl]-methanesulfonamide,
N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide (dofetilide),
N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide (UK-68798),
N-[4-(2-{[2-(4-METHANESULFONYLAMINO-PHENYL)-ETHYL]-METHYL-AMINO}-ETHOXY)-PHENYL]-METHANESULFONAMIDE DOFETILIDE,
N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methyl-amino]ethyl]phenyl]methanesulfonamide,
N-[4-[2-[methyl-[2-[4-(methylsulfonylamino)phenoxy]ethyl]amino]ethyl]phenyl]methanesulfonamide,
D0NW3X,
Dofetilide [USAN:INN:BAN],
Tikosyn, UK68798, Dofetilide,
CID71329,
ACN-040496,
C19-H27-N3-O5-S2,
CS-O-11629,
A8417,
C063533,
1-(4-methanesulfonamidophenoxy)-2-[N-(4-methanesulfonamidophenethyl)-N-methylamino]ethane,